MEI Pharma Inc (MEIP.OQ)

MEIP.OQ

About

MEI Pharma, Inc., formerly Marshall Edwards, Inc., is a development-stage oncology company. The Company is engaged in the development of drugs for the treatment of cancer. The Company focuses on the clinical development of therapeutics targeting cancer metabolism. The Company is a wholly owned subsidiary of Novogen Limited... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	2.30
Market Cap (Mil.):	$140.70
Shares Outstanding (Mil.):	17.12
Dividend:	--
Yield (%):	--

Financials

	MEIP.OQ	Industry	Sector
P/E (TTM):	--	46.63	34.30
EPS (TTM):	-2.80	--	--
ROI:	-64.54	1.55	18.43
ROE:	-64.54	2.77	19.30

Latest News about MEIP.OQ

» More MEIP.OQ News

Competitors

	Price	Change
Cadence Pharmaceuticals, Inc. (CADX.OQ)	$6.91	-0.06
Hi-Tech Pharmacal Co. (HITK.OQ)	$33.70	-0.68
A.P. Pharma, Inc. (APPA.OB)	$0.42	-0.00
China Yongxin Pharmaceuticals Inc (CYXN.PK)	$0.01	0.00
CytoDyn Inc (CYDY.PK)	$0.80	+0.03

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
MEI Pharma Provider: S&P Capital IQ Quantitative Report	$69.00 Buy
MEI Pharma Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
Thomson Reuters Stock Report - MEI PHARMA INCORPORATION (MEIP-O) Provider: Thomson Reuters Stock Report	$25.00 Buy
MEI Pharma, Inc. (MSHL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Provider: GlobalData	$250.00 Buy
MEI PHARMA INC (MEIP) Zacks Company Snapshot Provider: Zacks Investment Research Inc.	$12.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.